Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Maron and colleagues1 described the data from a multicenter registry collected on more than 500 patients with hypertrophic cardiomyopathy (HCM) who had received an implantable cardioverter-defibrillator for secondary or primary prevention of sudden death. According to that article, patients were diagnosed with HCM based on 2-dimensional echocardiographic evidence of a hypertrophied and nondilated left ventricle in the absence of another cardiac or systemic disease that could account for the magnitude of hypertrophy.
Refaat M. Prognosis of Apical Hypertrophic Cardiomyopathy. JAMA. 2007;298(17):2006. doi:10.1001/jama.298.17.2006-a